Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | TP53 | P04637 | 4/20 | 0.55 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.52 |
| ▸ | B3GNT2 | Q9NY97 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CFD | P00746 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL891057 | 0.89 | MAPT (0.53) | ALDH1A1SMN1; SMN2GAAKDM4EGLA | |
| SCHEMBL891155 | 0.85 | B3GNT2 (0.58) | ALDH1A1SMN1; SMN2GAAMAPTTP53 | |
| SCHEMBL891547 | 0.85 | B3GNT2 (0.48) | ALDH1A1SMN1; SMN2GAAKDM4EGLA | |
| SCHEMBL891255 | 0.84 | B3GNT2 (0.44) | ALDH1A1SMN1; SMN2GAAKDM4EGLA | |
| SCHEMBL891245 | 0.84 | KDM4E (0.48) | ALDH1A1GAAKDM4EGLAMAPT | |
| SCHEMBL1064027 | 0.81 | B3GNT2 (0.65) | ALDH1A1SMN1; SMN2GAAKDM4EMAPT | |
| SCHEMBL15282165 | 0.81 | MAOB (0.45) | ALDH1A1SMN1; SMN2GAAKDM4EGLA | |
| SCHEMBL891135 | 0.81 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2GAAKDM4EGLA | |
| SCHEMBL15282209 | 0.80 | MAPT (0.56) | ALDH1A1SMN1; SMN2GAAKDM4EGLA | |
| SCHEMBL891385 | 0.79 | B3GNT2 (0.51) | ALDH1A1SMN1; SMN2KDM4EMAPTB3GNT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268273-B1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON PHARMACEUTICALS INC (US) | 2017-06-28 | — | — | EP | claimed |
| CN-101420942-B | Small-molecule modulators of TRP-P8 activity | DENDREON CORP | 2014-03-12 | — | — | CN | claimed |
| EP-1986622-B1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORP (US) | 2013-10-02 | — | — | EP | claimed |
| EP-2268273-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2011-01-05 | — | — | EP | claimed |
| US-7772266-B2 | treating or preventing benign prostatic hyperplasia, enlarged prostate, acute urinary retention with 2-Isopropyl-5-methyl-cyclohexanecarboxylic acid (2-amino-2-phenyl-ethyl)-amide; agonists or antagonists of a transient receptor potential proteins; anticarcinogenic agent | DENDREON CORPORATION (US) | 2010-08-10 | — | — | US | claimed |
| US-7741355-B2 | Small-molecule modulators of TRP-p8 activity | DENDREON CORPORATION (US) | 2010-06-22 | — | — | US | claimed |
| WO-2009067410-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2009-05-28 | — | — | WO | claimed |
| EP-1986622-A2 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2008-11-05 | — | — | EP | claimed |
| US-20080255185-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2008-10-16 | — | — | US | claimed |
| US-20070232603-A1 | Small-molecule modulators of TRP-P8 activity | DENDREON CORPORATION (US) | 2007-10-04 | — | — | US | claimed |
| WO-2007095340-A2 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2007-08-23 | — | — | WO | claimed |
| EP-2268273-B1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON PHARMACEUTICALS INC (US) | 2017-06-28 | — | — | EP | disclosed |
| CN-101420942-B | Small-molecule modulators of TRP-P8 activity | DENDREON CORP | 2014-03-12 | — | — | CN | disclosed |
| US-8618155-B2 | Small-molecule modulators of Trp-p8 activity | DENDREON CORPORATION (US) | 2013-12-31 | — | — | US | disclosed |
| US-8614243-B2 | Small-molecule modulators of Trp-p8 activity | DENDREON CORPORATION (US) | 2013-12-24 | — | — | US | disclosed |
| WO-2009067410-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2009-05-28 | — | — | WO | disclosed |
| EP-1986622-A2 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20080255185-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
| US-20070232603-A1 | Small-molecule modulators of TRP-P8 activity | DENDREON CORPORATION (US) | 2007-10-04 | — | — | US | disclosed |
| WO-2007095340-A2 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232603-A1 | Small-molecule modulators of TRP-P8 activity | TRPC4, TRPC3, TRPC1 | ALDH1A1 4789/4885SMN1; SMN2 4023/4885GAA 4591/4885 |
| US-20080255185-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | TRPC4, TRPC3, TRPC1 | ALDH1A1 4789/4885SMN1; SMN2 4023/4885GAA 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.